聖諾醫藥-B(02257.HK)中期實現虧損4610萬美元、並無產生任何產品銷售收入
格隆匯8月31日丨聖諾醫藥-B(02257.HK)披露截至2022年6月30日止六個月的中期業績,集團並無產生任何產品銷售收入,錄得虧損4610萬美元,而上年同期則錄得虧損3350萬美元。集團的絕大部分淨虧損來自研發開支、行政開支及按公平值計入損益的金融負債的公平值變動。
其他收入由截至2021年6月30日止六個月的0.1百萬美元增加0.8百萬美元或659%至0.9百萬美元。該增加主要是由於集團於香港聯交所上市完成後獲得政府補助0.6百萬美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.